X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the collaboration, company aims to focus on the clinical development of PAN004, which is being evaluated in the preclinical studies for the treatment of acute respiratory distress syndrome.
Lead Product(s): PAN004
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PAN004
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Wacker Chemie AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 07, 2024
Details:
The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Evaxion Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
Under the new agreement, Pantherna’s mRNA platform and Astellas’ world-class drug discovery capabilities will be combined to promote research on the generation of regenerative medicine programs for new target organ using a direct reprogramming approach PTXmRNAs.
Lead Product(s): mRNA-based Regenerative Medicine
Therapeutic Area: Technology Product Name: PTXmRNAs
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
